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Abstract Although the brain is an important target for the
human immunodeficiency virus type 1 (HIV) and viral infection
causes neuronal degeneration and dementia, the mechanisms
responsible for HIV transcription in neuronal cells are largely
unknown. We show here that retinoic acid (RA) stimulates HIV
transcription in human neuronal SH-SY5Y cells. The steroid
receptor coactivator 1 (SRC-1) enhances the transcriptional
response to RA, and the viral protein Tat cooperates with RA
and SRC-1 to induce a strong transactivation. These results
suggest that retinoid receptors could play an important role as
activators of viral gene expression in the human brain.
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1. Introduction
Human immunode¢ciency virus type 1 (HIV) causes infec-
tions in the brain, leading to massive neuronal damage and to
AIDS dementia complex [1]. Although microglial cells appear
to be the major target brain cells for the virus, infection of
neuronal cells appears to cause neuronal loss and dysfunction
[2,3]. It is therefore important to understand the regulation of
HIV-1 gene expression in neuronal cells, which appear to
possess the machinery responsible for HIV transcription [4^6].
The retinoic acid (RA) receptors are members of the ste-
roid/thyroid hormone receptor superfamily which act as li-
gand-inducible transcription factors by binding to responsive
elements (HREs) normally located in regulatory regions of
target genes [7]. Upon ligand binding, the receptors undergo
conformational changes which facilitate recruitment of coac-
tivators responsible for gene activation [8,9]. The steroid hor-
mone receptor coactivator 1 (SRC-1/NCoA1) [10] is one of
such coactivators. A HRE located between nucleotides 3352
and 3320 in the HIV long terminal repeat (LTR) binds ret-
inoid receptors (RARs and RXRs) [11,12]. However, depend-
ing on the cell type it has been found that RA can either
stimulate or inhibit the activity of the HIV LTR [13^17].
The human neuroblastoma cell line SH-SY5Y, which di¡er-
entiates in the presence of RA, provides an excellent model to
analyze the e¡ect of retinoids on neuronal cells. In this study
we show a strong activation of the HIV LTR by RA in SH-
SY5Y cells. This activation is enhanced by the coactivator
SRC-1 and the viral transactivator Tat. Surprisingly, activa-
tion by RA is only slightly reduced in an LTR construct in
which the HRE had been mutated. Furthermore, sequences
within the core promoter bind RAR^RXR heterodimers and
are su⁄cient for RA-dependent HIV LTR stimulation. These
results show that the HIV LTR contains multiple binding sites
for retinoid receptors and that retinoids could play a role in
the regulation of HIV LTR activity in neurons and during
progress of the neurological damage in AIDS patients.
2. Materials and methods
2.1. Plasmids
The plasmid 3453HIV-Luc contains HIV-1 LTR sequences from
3453 to +80 fused to luciferase, and in 3453vNF-UBHIV^Luc the
GCG motif of both NF-UB binding sites located at 3104/376 was
mutated to TCT [18]. Deletion mutants extending to nucleotides
3453, 3104, 376 and 328 of the HIV LTR were previously de-
scribed [12]. To construct plasmid 3453vHREHIV-Luc, site-directed
mutagenesis by PCR was performed using the oligonucleotide 5P-
CCAGGATCTAGATATCCACTGTGCTTTGG-3P in which both
hemisites of the HRE located between nucleotides 3356 and 3320
were mutated. The expression vector for Tat has been cloned in
pcDNA3, which contains the cytomegalovirus (CMV) promoter.
The truncated receptor RARvAF-2 contains amino acids 1^419 of
human RARK ; and RXRvAF-2 contains amino acids 1^445 of hu-
man RXRK [19]. Expression vector for SRC-1 [20] has been previ-
ously described.
2.2. DNA transfection
SH-SY5Y cells were transiently transfected by the calcium phos-
phate method with 4 Wg of reporter constructs as previously described
[12]. The cells were incubated for 48 h with RA or tumor necrosis
factor K (TNFK), and luciferase activity determined. Each treatment
was performed in triplicate cultures that normally exhibited less than
10^15% variation and each experiment was repeated at least three
times with similar di¡erences in regulated expression. The data are
shown as the mean þ S.D.
2.3. Protein preparations
The glutathione S-transferase (GST) fusion proteins, GST^RAR,
GST^TR, GST^VDR and GST^RXR [21,22] were expressed in the
bacterial strain BL21(DE3) and puri¢ed by standard techniques. The
expression of correctly sized proteins was monitored by SDS^PAGE.
2.4. Gel mobility shift assays
Electrophoretic mobility shift assays were performed using either
recombinant receptors or 5 Wg of SH-SY5Y nuclear extracts as
previously described [12]. The UB oligonucleotides used were: 5P-
CAAGGGACTTTCCGCTGGGGACTTTCCAGG-3P corresponding
to sequences 3104 to 376 of the HIV-1 LTR containing the
two UB binding sites, 5P-CAATCTACTTTCCGCTGTCTACTTT-
CCAGG-3P in which both binding sites were mutated. The oligonu-
cleotide 5P-AGGGAGGCGTGGCCTGGGCGGGACTGGGGAGT-
CCC-3P corresponds to the HIV LTR Sp1 sites from 375 and 344.
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Oligonucleotides containing nuclear receptor binding sites were:
5P-CCAGGGGTCAGATATCCACTGACCTTTGG-3P encompassing
the HRE present in the HIV LTR, and the mutated oligonucleotide
described above. Di¡erent labeled promoter fragments (3109/+89;
378/+89; 335/+89; +31/+89 and 335/+30) obtained by PCR were
also used as probes in gel retardation assays. The antisense oligonu-
cleotides used were: 5P-GCCAAGCTTTATTGAGGCP-3P (+72/+89)
and 5P-CTCAGATCTGGTCTAACC-3P (+13/+30). The sense oligo-
nucleotides were the following: 5P-GTTACAAGGGACTTTCGCG-3P
(for 3109); 3P-AGGGAGGCGTGGCCTGG-3P (for 378); 5P-AGA-
TGCTGCATATAAGCAGC-3P (for 335); and 5P-CCTGGGAGCT-
TTTCTGGC-3P (for +31).
3. Results
As shown in Fig. 1, incubation of SH-SY5Y cells with RA
signi¢cantly increased the activity of 3453HIV^Luc. This ac-
tivation was similar in its extent to that caused by TNFK, a
potent inducer of the LTR (data not shown). Removal of the
LTR sequences from 3453 to 3104 reduced by about 50%
basal promoter activity. However, a signi¢cant response to
RA was observed with the 3104HIV^Luc construct, which
does not contain the previously identi¢ed HRE. These results
suggest that elements additional to the HRE contribute to
HIV activation by RA. The core HIV promoter contains
two binding sites for NF-UB (nucleotides 3104 to 381) in
close proximity to three binding sites for the transcription
factor Sp1 (nucleotides 377 to 346), and a cooperative inter-
action between both factors is required for activation of the
virus in non-neuronal cells [23]. An LTR fragment extending
to 376 showed an extremely low luciferase activity, indicating
that NF-UB sites are essential for basal activation of the HIV
LTR in SH-SY5Y cells. However, as shown in the inset, stim-
ulation by RA was similar in magnitude to that found for the
construct 3104HIV-Luc. The importance of the NF-UB ele-
ments was also examined with a plasmid (3453vNFUB^HIV^
Luc) in which the UB sites had been mutated. This mutation
caused a dramatic decrease of luciferase activity, though both
basal and RA-dependent stimulation were similar to that
found for the construct 376HIV^Luc. Therefore, the induc-
tion of HIV transcription by RA appears to be NF-UB-inde-
pendent. Furthermore, SH-SY5Y cells do not contain signi¢-
cant amounts of constitutive p50/p65 NF-UB heterodimers in
the nucleus and RA does not promote NF-UB activation in
SH-SY5Y cells (data not shown). Deletion of the LTR to 328
bp, which eliminates the three Sp1 sites, essentially abolished
promoter activity and under these conditions the e¡ect of RA
was undetectable.
To analyze the functional role of the HRE in the response
to RA, both hemisites of this element were mutated in the
3453HIV LTR construct (Fig. 2). Fig. 2A shows that this
mutation abolishes the binding of nuclear proteins from SH-
SY5Y cells, and also the binding of recombinant RAR^RXR
heterodimers. Fig. 2B shows that mutation of the HRE did
not a¡ect basal activity of the LTR and had little inhibitory
e¡ect on RA-mediated induction: RA caused a six-fold in-
crease of HIV^Luc activity, whereas the mutated construct
showed a four-fold increase. Therefore, although the previ-
ously identi¢ed HRE participates in the response to RA, addi-
tional elements are required for full HIV LTR stimulation by
the retinoid.
Since sequences contained between 3104 and +89 were able
to confer responsiveness to RA, additional binding sites for
retinoid receptors should be located downstream of the char-
Fig. 1. Elements of the HIV LTR mediating regulation by RA. A:
Schematic representation of the HIV LTR. The positions of the ar-
rows indicate the deletion mutants of the LTR which were used.
B: Constructs extending to 3453, 3104, 376 and 328, as well as a
construct in which the NF-UB sites have been mutated in the con-
text of the 3453 plasmid (3453vNF-UB), were transfected into SH-
SY5Y cells. Luciferase activity was determined in untreated cells
and in cells treated with 1 WM RA for 48 h. The inset represents a
magni¢cation of the luciferase values obtained in the plasmids
showing low basal activity.
Fig. 2. Role of the HRE located between 3352 and 3320 on RA-
mediated activation. A: Nuclear extracts (NE) from cells treated
with RA from 24 h, as well as recombinant RAR^RXR (100 ng)
were subjected to mobility shift assays with the wild-type HRE oli-
gonucleotide (HREwt) or with an oligonucleotide in which both
hemisites of the HRE had been mutated (HRE mut.). B: SH-SY5Y
cells were transfected with 4 Wg of 3453HIV^Luc, which contains
the HREwt, or with a construct containing the HRE mutation used
in B. Luciferase activity was determined in cells treated in the pres-
ence and absence of 1 WM RA for 48 h.
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acterized HRE. To determine the presence of these putative
sites, di¡erent labeled HIV LTR fragments were subjected to
gel retardation assays with recombinant RAR and/or RXR.
Fig. 3A shows that the fragment 3104/+89 bound RAR^
RXR heterodimers (lane 12). This fragment contains the
NF-UB sites which have been described to bind receptor het-
erodimers [24]. However, as shown in Fig. 3D, although
strong binding of thyroid hormone receptor heterodimers
(TR^RXR) to the UB sites was observed (lane 3), we were
not able to detect binding of RAR^RXR to these sequences
(lane 2). The vitamin D3 receptor (VDR) was not able to bind
to these sites either (lane 3). The promoter fragment 376/+89,
however, bound RAR^RXR heterodimers (Fig. 3A, lane 8),
con¢rming that the UB sites were not required for RA recep-
tor binding. This fragment still contains the Sp1 sites and an
overlapping element [24,25] which binds TR and TR^RXR
heterodimers (Fig. 3E, lanes 5 and 8). RAR and RAR^
RXR also bind these sites (Fig. 3E, lanes 2 and 6), although
very weakly as compared with TR. Other binding elements for
retinoid receptors located closer to the transcription initiation
site are present in the LTR, as demonstrated by the ¢nding
that sequences contained between nucleotides 335 and +89
bound strongly RAR^RXR heterodimers (Fig. 3A, lane 4).
To further analyze binding of RAR^RXR to the proximal
promoter, this sequence was split into two new fragments,
one containing nucleotides 335 to +30, and the other nucleo-
tides +31 to +80. Fig. 3B compares the binding of retinoid
receptors to the three sequences. It was observed that RAR^
RXR heterodimers were able to bind to the two fragments,
although binding to sequences 335/+30 was stronger than
that observed with +31/+89. Fig. 3C shows that both sequen-
ces bound also TR^RXR and VDR^RXR heterodimers.
Binding to the di¡erent fragments was speci¢c as it was com-
peted in the presence of an excess of the corresponding un-
labeled sequence, as well as by an excess of nucleotides con-
taining consensus HREs for the di¡erent receptors (not
illustrated). Taken together, these results demonstrate that
the proximal HIV promoter contains at least three di¡erent
binding sites for retinoid receptors which can contribute to
stimulation by RA in SH-SY5Y cells.
Fig. 3. Binding of nuclear receptors to core HIV promoter sequen-
ces. A and B: Mobility shift assays were performed with recombi-
nant RAR and/or RXR (75 ng) and the labeled fragments of the
LTR indicated at the top of the panels. C: Binding of recombinant
RAR, TR and VDR, alone or in combination with RXR, to the la-
beled HIV LTR fragments 335/+30 and +31/+89. D and E: Oligo-
nucleotides encompassing sequences 3104/376 and 375/344 which
contain the NF-UB and Sp1 sites of the LTR, respectively, were
used for gel retardation assays with RAR, TR or VDR in the pres-
ence and absence of RXR. The ¢rst lane for each fragment or oli-
gonucleotide shows the mobility of the unretarded probe, and the
arrows indicate the retarded complexes formed with the receptor
heterodimers.
Fig. 4. Synergism of Tat with RA. In the left panel the indicated constructs of the HIV LTR were transfected into SH-SY5Y cells either alone
or in combination with 100 ng of an expression vector encoding the viral activator Tat. Luciferase activity was determined in untreated cells
and in cells incubated with 1 WM RA for 48 h (black bars). The inset represents a magni¢cation of the luciferase activity obtained in cells
transfected with the last three plasmids. Luciferase values were determined in parallel in cells transfected with 3453HIV^Luc and incubated in
the presence and absence of 10 ng/ml TNFK (right panel).
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The viral protein Tat is critical for activation of HIV tran-
scription [23]. To determine whether a functional interaction
between Tat and RA occurs, the constructs indicated in Fig. 1
were cotransfected into SH-SY5Y cells with an expression
vector encoding Tat. The viral protein alone had little e¡ect
on 3453HIV^Luc activity but, as shown in Fig. 4A, enhanced
signi¢cantly the response to RA. With respect to the basal
uninduced levels, the activity of the the HIV LTR increased
by more than 100-fold in the presence of Tat and the retinoid.
This stimulation had a similar magnitude as that produced by
TNFK in cells expressing Tat (Fig. 4B). Deletion of the reg-
ulatory region and the NF-UB sites reduced luciferase activity,
but a clear cooperation of RA with Tat was still detected (Fig.
4A). In contrast, 328HIV^Luc, in which the Sp-1 sites had
been deleted, was inactive even in the presence of Tat.
Ligand-dependent transactivation by nuclear receptors de-
pends on the presence of an autonomous activation function
domain (AF-2), which is located in the C-terminal region and
is required for binding of coactivators [8,9]. In order to ana-
lyze the role of this domain in the activation of HIV tran-
scription by RA, SH-SY5Y cells were cotransfected with
3453HIV^Luc and expression vectors for deletion mutants
of RAR and RXR which lacked the core AF-2 domain. As
shown in Fig. 5A, the RAR mutant behaved as an inhibitor of
activation mediated by the endogenous receptors and blocked
the response to RA. In contrast, the truncated RXR did not
signi¢cantly a¡ect the response to the retinoid. The e¡ect of
transfection with expression vectors encoding the coactivator
SRC-1 on the response to two concentrations of RA (10 nM
and 1 WM) is illustrated in Fig. 5B. RA increased LTR activity
in a dose-dependent manner and SRC-1 signi¢cantly en-
hanced this response. The possibility that SRC-1 could coop-
erate with Tat to activate the LTR was also explored. Fig. 5C
shows that both Tat and SRC-1 independently increased RA-
dependent activation and that this stimulation was maximal in
SH-SY5Y cells expressing both Tat and SRC-1.
4. Discussion
Studies in transgenic mice have revealed that the promoter
of neurotropic HIV-1 strains directs viral gene expression in
neurons throughout the nervous system [3]. These results im-
ply that neurons possess a speci¢c transcription machinery
capable of HIV-1 activation. Since RA is well known to act
as an inducer of neuronal function, we have analyzed the
regulation of HIV gene transcription by RA in human neuro-
nal cells. Our results indicate that the retinoid is a potent
activator of the HIV LTR in these cells. In fact, stimulation
by RA was as strong as that caused by TNFK, a prototypic
HIV activator [26]. It has been suggested that the therapeutic
use of retinoid antagonists could provide a means of repres-
sing viral replication by inhibiting retinoid-dependent tran-
scription [13,14]. Our data indicate that this approach could
indeed be useful to inhibit HIV gene expression in neuronal
cells. However, it is unclear whether this pharmacological
strategy should be e¡ective, since depending on the cell
type both suppressive and inductive e¡ects of RA on HIV
expression and virus production have been documented
[27,28].
The HRE located in the HIV LTR regulatory region [11]
was expected to be responsible for RA-dependent stimulation.
However, our data reveal that this HRE does not play a
major role in RA-mediated stimulation in SH-SY5Y cells.
When this sequence was deleted other downstream-located
sequences were able to mediate signi¢cant stimulation by the
retinoid. Among these elements the UB sites were candidates
to be involved in regulation by RA. However, our data show
that stimulation of HIV gene transcription by RA appears to
be NF-UB-independent, although the UB sites are responsible
for most basal LTR activity in SH-SY5Y cells. SH-SY5Y cell
nuclei do not contain constitutively active p50/p50 homo-
dimers or p50/p65 heterodimers and therefore other still un-
identi¢ed nuclear factors which bind to the UB sites must be
responsible for basal HIV gene expression in these cells. We
have reported similar results in another neuronal cell model,
PC12 cells, in which several proteins, di¡erent from p50 and
p65, bind to the UB sites and activate transcription from the
LTR [12]. The transcription factor Sp1 also plays an impor-
tant role in HIV gene expression in di¡erent cell types, and
there was the possibility that association of retinoid receptors
with the Sp1 sites could be responsible for RA-dependent
induction in SH-SY5Y cells. However, although in agreement
Fig. 5. In£uence of nuclear receptor coactivators on the HIV response to RA. A: SH-SY5Y cells were transfected with 3453HIV-Luc alone or
in combination with 2 Wg of expression vectors for truncated versions of RAR and RXR lacking the AF-2 domain. Luciferase activity was de-
termined 48 h later in untreated cells and in cells treated with 1 WM RA. B: Cells were cotransfected with the reporter construct and 2 Wg of
an expression vector for the coactivator SRC-1. Luciferase activity was determined in cells treated for 48 h with the concentrations of RA indi-
cated. C: 3453HIV^Luc was cotransfected with 2 Wg of SRC-1 and/or 200 ng of Tat vectors, and luciferase activity determined after 48 h in
cells treated in the presence and absence of 1 WM RA.
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with previous observations [24,25] we ¢nd that these motifs
are strong binding sites for TRs, they are only weak binding
sites for RA receptors. In contrast, our studies document the
existence of previously unrecognized nuclear receptor binding
sites in the HIV core promoter located both upstream and
downstream of the TATA box. Like other HREs, homo-
dimers associate only weakly to these motifs, which bind pref-
erentially RAR^RXR heterodimers. In contrast with the LTR
UB or Sp1 motifs which are rather selective for TR^RXR,
these proximal elements can bind RAR^RXR, TR^RXR
and VDR^RXR heterodimers with a similar potency and
are, therefore, potential targets for regulation by diverse nu-
clear receptors. The existence of various binding sites both in
the modulatory and in the proximal promoter regions stresses
the importance of nuclear receptor signalling pathways in
HIV transcription. This multiplicity likely ensures transcrip-
tional regulation of di¡erent virus variants by the receptors
even after mutation of one particular receptor binding site.
Our results also show that a carboxy-terminal truncated
RAR exerts a dominant negative activity blocking stimulation
by RA. This shows that RAR AF-2 domain, involved in
coactivator recruitment, is essential for retinoid-dependent
transactivation of the LTR. In contrast, an equivalent RXR
mutant did not a¡ect this response. This ¢nding is compatible
with the idea that RXR acts as a heterodimeric partner with
RAR, but not as a RXR^RXR homodimer, to stimulate HIV
gene expression in SH-SY5Y cells. RXR would thus be re-
quired for high a⁄nity binding to the HREs, but the AF-2
domain of RXR would be dispensable for the ligand-depen-
dent transcriptional activity of the RAR^RXR heterodimer.
The important functional role of coactivators in the regulation
of HIV gene expression by RAR is demonstrated by the in-
crease in RA-dependent transactivation observed in the pres-
ence of SRC-1, a coactivator which binds the receptor AF-2
domain in a ligand-dependent manner [10]. These results dem-
onstrate a novel role of this protein in HIV gene expression.
Other coactivators appear to play a role in HIV gene tran-
scription. Thus, CBP/p300 which acts as a coactivator for NF-
UB, Tat and diverse nuclear receptors, also has been shown to
enhance HIV LTR activity in non-neuronal cells [29,30].
We found that RA synergizes with the viral protein Tat to
activate HIV gene transcription in neuronal cells. The mech-
anism underlying this cooperation is still unclear. A physical
association of Tat with TR has been documented [31], and it
is not unlikely that RAR could also interact with the viral
protein. Binding of Tat and the receptors to their close bind-
ing sites, as well as coactivator recruitment, could facilitate
targeting of the transcriptional machinery to the promoter
and the synergistic activation.
Our ¢ndings show the participation of receptors, transcrip-
tion factors and coactivators in the stimulation of HIV gene
expression by RA in neuronal cells. Synergism between these
factors and Tat demonstrates that both host and viral proteins
cooperate to induce RA-mediated transcription of HIV in
these cells. Because the LTR represents the main regulatory
region that determines expression of genes necessary for viral
replication, our results suggest that retinoid receptors may
play a role during the infectious process in brain cells and
in the progress of neurological damage in AIDS patients.
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